The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Mutations in AML: prognostic and therapeutic implications
Open accessAbstract
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the proliferation and aberrant differentiation of immature clonal myeloid cells. The prognosis of AML is variable, based on clinical features such as patient age, performance status, and comorbidities, as well as leukemia-specific genetic features including cytogenetics and molecular classification. The modern application of next-generation sequencing technology has uncovered marked heterogeneity and genomic complexity within AML, based on the presence or absence of cooperating mutations within functional categories such as epigenetic regulators, cell signaling and proliferation pathways, and master hematopoietic transcription factors. Although the treatment of AML has hitherto changed little in the past 40 years, the enhanced scientific understanding of AML pathophysiology and leukemogenesis has led to the recent development of multiple targeted and selective treatment approaches, and our increasing awareness of functional AML subsets will be evermore used to inform rational and personalized treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Grimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., Burnett, A. K., & on behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,938
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
Age and acute myeloid leukemia
Appelbaum, F. R., Gundacker, H., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,350
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Kantarjian, H. M., Thomas, X. G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J.-P., Chou, W.-C., Buckstein, R., Cermak, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,169
Dnmt3a is essential for hematopoietic stem cell differentiation
Challen, G. A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J. S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., et al. (2012) · Nature Genetics · doi:10.1038/ng.1009 · Cited by 1,122
Konopleva, M., Pollyea, D. A., Potluri, J., Chyla, B., Hogdal, L., Busman, T., McKeegan, E., Salem, A. H., Zhu, M., Ricker, J. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0313 · Cited by 1,064
Self-citationAcute myeloid leukemia ontogeny is defined by distinct somatic mutations
Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991
Juliusson, G., Antunovic, P., Derolf, Å., Lehmann, S., Möllgård, L., Stockelberg, D., Tidefelt, U., Wahlin, A., & Höglund, M. (2009) · Blood · doi:10.1182/blood-2008-07-172007 · Cited by 987
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
Döhner, K., Schlenk, R. F., Habdank, M., Scholl, C., Rücker, F. G., Corbacioglu, A., Bullinger, L., Fröhling, S., Döhner, H., & for the AML Study Group (AMLSG) (2005) · Blood · doi:10.1182/blood-2005-05-2164 · Cited by 849
Assessment of Minimal Residual Disease in Standard-Risk AML
Ivey, A., Hills, R. K., Simpson, M. A., Jovanovic, J. V., Gilkes, A., Grech, A., Patel, Y., Bhudia, N., Farah, H., Mason, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507471 · Cited by 845
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity
Spinner, M. A., Sanchez, L. A., Hsu, A. P., Shaw, P. A., Zerbe, C. S., Calvo, K. R., Arthur, D. C., Gu, W., Gould, C. M., Brewer, C. C., et al. (2014) · Blood · doi:10.1182/blood-2013-07-515528 · Cited by 712
RNA splicing factors as oncoproteins and tumour suppressors
Dvinge, H., Kim, E., Abdel-Wahab, O., & Bradley, R. K. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.51 · Cited by 687
Rücker, F. G., Schlenk, R. F., Bullinger, L., Kayser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.-M., Holzmann, K., Gaidzik, V. I., et al. (2012) · Blood · doi:10.1182/blood-2011-08-375758 · Cited by 683
Bloomfield, C. D., Lawrence, D. D., Byrd, J. C., Carroll, A. J., Pettenati, M. J., Tantravahi, R. V., Patil, S., Davey, F. R., Berg, D. T., Schiffer, C. A., et al. (1998) · PubMed · Cited by 682
Acute myeloid leukemia: Epidemiology and etiology
Deschler, B., & Lübbert, M. (2006) · Cancer · doi:10.1002/cncr.22233 · Cited by 646
Dores, G. M., Devesa, S. S., Curtis, R. E., Linet, M. S., & Morton, L. M. (2012) · Blood · doi:10.1182/blood-2011-04-347872 · Cited by 636
ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression
Abdel-Wahab, O., Adli, M., LaFave, L. M., Gao, J., Hricik, T., Shih, A. H., Pandey, S., Patel, J. P., Chung, Y. R., Koche, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.032 · Cited by 599
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W.-J., Zhao, F., Medeiros, B. C., Tyvoll, D. A., & Majeti, R. (2015) · Nature Medicine · doi:10.1038/nm.3788 · Cited by 577
Wouters, B. J., Löwenberg, B., Erpelinck-Verschueren, C. A. J., van Putten, W. L. J., Valk, P. J. M., & Delwel, R. (2009) · Blood · doi:10.1182/blood-2008-09-179895 · Cited by 566
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Bejar, R., Lord, A., Stevenson, K., Bar-Natan, M., Pérez-Ladaga, A., Zaneveld, J., Wang, H., Caughey, B., Stojanov, P., Getz, G., et al. (2014) · Blood · doi:10.1182/blood-2014-06-582809 · Cited by 562
Röllig, C., Serve, H., Hüttmann, A., Noppeney, R., Müller-Tidow, C., Krug, U., Baldus, C. D., Brandts, C. H., Kunzmann, V., Einsele, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00362-9 · Cited by 401
Wlodarski, M. W., Hirabayashi, S., Pastor, V., Starý, J., Hasle, H., Masetti, R., Dworzak, M., Schmugge, M., van den Heuvel-Eibrink, M., Ussowicz, M., et al. (2016) · Blood · doi:10.1182/blood-2015-09-669937 · Cited by 392
Ravandi, F., Estey, E., Jones, D., Faderl, S., O'Brien, S., Fiorentino, J., Pierce, S., Blamble, D., Estrov, Z., Wierda, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6130 · Cited by 376
Self-citationJw, Y., Hj, W., Rr, E., & Jf, H. (1973) · PubMed · Cited by 366
Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352
Lee, S. C.-W., Dvinge, H., Kim, E., Cho, H., Micol, J.-B., Chung, Y. R., Durham, B. H., Yoshimi, A., Kim, Y. J., Thomas, M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4097 · Cited by 347
Büchner, T., Berdel, W. E., Haferlach, C., Haferlach, T., Schnittger, S., Müller-Tidow, C., Braess, J., Spiekermann, K., Kienast, J., Staib, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4245 · Cited by 338
Becker, H., Marcucci, G., Maharry, K., Radmacher, M. D., Mrózek, K., Margeson, D., Whitman, S. P., Wu, Y.-Z., Schwind, S., Paschka, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1496 · Cited by 338
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
DiNardo, C. D., Ravandi, F., Agresta, S., Konopleva, M., Takahashi, K., Kadia, T., Routbort, M., Patel, K. P., Brandt, M., Pierce, S., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24072 · Cited by 325
Self-citationFröhling, S., Schlenk, R. F., Kayser, S., Morhardt, M., Benner, A., Döhner, K., Döhner, H., & for the German-Austrian AML Study Group (2006) · Blood · doi:10.1182/blood-2006-04-014324 · Cited by 300
Pratcorona, M., Brunet, S., Nomdedéu, J., Ribera, J. M., Tormo, M., Duarte, R., Escoda, L., Guàrdia, R., Queipo de Llano, M. P., Salamero, O., et al. (2013) · Blood · doi:10.1182/blood-2012-06-431122 · Cited by 285
Gaidzik, V. I., Teleanu, V, Papaemmanuil, E., Weber, D., Paschka, P., Hahn, J., Wallrabenstein, T., Kolbinger, B., Köhne, C. H., Horst, H. A., et al. (2016) · Leukemia · doi:10.1038/leu.2016.126 · Cited by 279
Mendler, J. H., Maharry, K., Radmacher, M. D., Mrózek, K., Becker, H., Metzeler, K. H., Schwind, S., Whitman, S. P., Khalife, J., Kohlschmidt, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.6652 · Cited by 268
Im, A. P., Sehgal, A. R., Carroll, M. P., Smith, B. D., Tefferi, A., Johnson, D. E., & Boyiadzis, M. (2014) · Leukemia · doi:10.1038/leu.2014.124 · Cited by 267
Medeiros, B. C., Satram-Hoang, S., Hurst, D., Hoang, K. Q., Momin, F., & Reyes, C. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2351-x · Cited by 259
Owen, C. J., Toze, C. L., Koochin, A., Forrest, D. L., Smith, C. A., Stevens, J. M., Jackson, S. C., Poon, M.-C., Sinclair, G. D., Leber, B., et al. (2008) · Blood · doi:10.1182/blood-2008-05-156745 · Cited by 242
Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation
Mayle, A., Yang, L., Rodriguez, B., Zhou, T., Chang, E., Curry, C. V., Challen, G. A., Li, W., Wheeler, D., Rebel, V. I., et al. (2015) · Blood · doi:10.1182/blood-2014-08-594648 · Cited by 235
Schnittger, S., Eder, C., Jeromin, S., Alpermann, T., Fasan, A., Grossmann, V, Kohlmann, A., Illig, T., Klopp, N., Wichmann, H.-E., et al. (2013) · Leukemia · doi:10.1038/leu.2012.262 · Cited by 211
Survival and cure of acute myeloid leukaemia in England, 1971‐2006: a population–based study
Shah, A., Andersson, T. M. ‐., Rachet, B., Björkholm, M., & Lambert, P. C. (2013) · British Journal of Haematology · doi:10.1111/bjh.12425 · Cited by 206
Pabst, T., Eyholzer, M., Haefliger, S., Schardt, J., & Mueller, B. U. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5563 · Cited by 201
Secondary mutations as mediators of resistance to targeted therapy in leukemia
Daver, N. G., Cortes, J. E., Ravandi, F., Patel, K. P., Burger, J. A., Konopleva, M. Y., & Kantarjian, H. M. (2015) · Blood · doi:10.1182/blood-2014-10-605808 · Cited by 170
Self-citationPabst, T., Eyholzer, M., Fos, J., & Mueller, B. U. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604977 · Cited by 163
Stone, R. M., Mandrekar, S., Sanford, B. L., Geyer, S., Bloomfield, C. D., Dohner, K., Thiede, C., Marcucci, G., Lo-Coco, F., Klisovic, R. B., et al. (2015) · Blood · doi:10.1182/blood.v126.23.6.6 · Cited by 159
Borthakur, G. M., Popplewell, L. L., Boyiadzis, M. M., Foran, J. M., Platzbecker, U., Vey, N., Walter, R. B., Olin, R. L., Raza, A., Giagounidis, A. A. N., et al. (2016) · Cancer · doi:10.1002/cncr.29986 · Cited by 146
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
Ravandi, F., Kantarjian, H., Faderl, S., Garcia-Manero, G., O’Brien, S., Koller, C., Pierce, S., Brandt, M., Kennedy, D., Cortes, J., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2009.10.001 · Cited by 125
Self-citationPreclinical efficacy of MEK inhibition in Nras-mutant AML
Burgess, M. R., Hwang, E., Firestone, A. J., Huang, T. Q., Xu, J., Zuber, J. A., Bohin, N., Wen, T., Kogan, S. C., Haigis, K. M., et al. (2014) · Blood · doi:10.1182/blood-2014-05-574582 · Cited by 118
Burnett, A. K., Hills, R. K., Green, C. L., Jenkinson, S., Koo, K., Patel, Y., Guy, C., Gilkes, A., Milligan, D. W., Goldstone, A. H., et al. (2009) · Blood · doi:10.1182/blood-2009-08-236588 · Cited by 118
Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis
Jacob, B., Osato, M., Yamashita, N., Wang, C. Q., Taniuchi, I., Littman, D. R., Asou, N., & Ito, Y. (2009) · Blood · doi:10.1182/blood-2009-07-232249 · Cited by 114
Dinardo, C. D., Bannon, S. A., Routbort, M. J., Franklin, A. R. K., Mork, M. E., Armanios, M. Y., Mace, E. M., Orange, J. S., Jeff‐Eke, M., Churpek, J. E., et al. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.04.001 · Cited by 91
Self-citationStein, E. M., Altman, J. K., Collins, R. H., DeAngelo, D. J., Fathi, A. T., Flinn, I. W., Frankel, A. E., Levine, R. L., Medeiros, B. C., Patel, M. R., et al. (2014) · Blood · doi:10.1182/blood.v124.21.115.115 · Cited by 90
Devillier, R., Mas, V. M., Gelsi‐Boyer, V., Demur, C., Murati, A., Corre, J., Prébet, T., Bertoli, S., Brecqueville, M., Arnoulet, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3460 · Cited by 81
Why methylation is not a marker predictive of response to hypomethylating agents
Voso, M. T., Santini, V., Fabiani, E., Fianchi, L., Criscuolo, M., Falconi, G., Guidi, F., Hohaus, S., & Leone, G. G. M. (2014) · Haematologica · doi:10.3324/haematol.2013.099549 · Cited by 78
Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia
Falini, B., Brunetti, L., & Martelli, M. P. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1509584 · Cited by 74
Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis
Eriksson, A., Lennartsson, A., & Lehmann, S. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.009 · Cited by 72
Alpermann, T., Schnittger, S., Eder, C., Dicker, F., Meggendorfer, M., Kern, W., Schmid, C., Aul, C., Staib, P., Wendtner, C., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.133819 · Cited by 72
Stein, E. M., Dinardo, C. D., Altman, J. K., Collins, R. H., DeAngelo, D. J., Kantarjian, H. M., Sekeres, M. A., Fathi, A. T., Flinn, I. W., Frankel, A. E., et al. (2015) · Blood · doi:10.1182/blood.v126.23.323.323 · Cited by 72
Self-citationDinardo, C. D., Pollyea, D. A., Pratz, K. W., Thirman, M. J., Letai, A. G., Frattini, M. G., Jonas, B. A., Leverson, J. D., Zhu, M., Dunbar, M., et al. (2015) · Blood · doi:10.1182/blood.v126.23.327.327 · Cited by 62
Self-citationBadar, T., Patel, K. P., Thompson, P. A., Dinardo, C. D., Takahashi, K., Cabrero, M., Borthakur, G. M., Cortes, J. E., Konopleva, M. Y., Kadia, T. M., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.10.005 · Cited by 58
Self-citationRoles of IDH1/2 and TET2 mutations in myeloid disorders
Inoue, S., Lemonnier, F., & Mak, T. W. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1973-7 · Cited by 57
Dinardo, C. D., de Botton, S., Pollyea, D. A., Stein, E. M., Fathi, A. T., Roboz, G. J., Collins, R. H., Swords, R. T., Flinn, I. W., Altman, J. K., et al. (2015) · Blood · doi:10.1182/blood.v126.23.1306.1306 · Cited by 57
Self-citationGetting a handle on hereditary CEBPA mutations
Dinardo, C. D. (2015) · Blood · doi:10.1182/blood-2015-07-657908 · Cited by 46
Self-citationMolecularly targeted therapies for acute myeloid leukemia
Stein, E. M. (2015) · Hematology · doi:10.1182/asheducation-2015.1.579 · Cited by 26
Cited by
Fischer, S., Weber, L. M., Stielow, B., Frech, M., Simon, C., Geller, M., Könnecke, J., Finkernagel, F., Forné, I., Nist, A., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae437 · Cited by 10
Metadata
- Authors
- DiNardo, C. D., & Cortes, J. E.
- Venue
- Hematology
- Publisher
- American Society of Hematology
- Published
- 2016-12-02
- Volume
- 2016
- Issue
- 1
- Pages
- 348-355
- ISSN
- 1520-4383 (ISSN-L)
- 1520-4391
- OpenAlex
- W2558961618
- Cited by
- 268
- References
- 75
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.